LB Pharmaceuticals LBRX
Drug Manufacturers - General, Healthcare
$39.04
−1.66%
- Market cap
- $1.3B
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −6.6%
Charts
Financials
| Income statement | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|
| R&D | $10.7M | $376K | $3.4M | $2.4M | $2.4M−77% | $8.5M+2156% | $14.6M+328% | $44.1M+1724% |
| SG&A | $5.4M | $5.2M | $3M | $2.4M | $2.8M−48% | $5.4M+4% | $7.5M+148% | $9.8M+301% |
| Pre-tax income | −$14.2M | −$5.1M | −$5.3M | −$4.9M | −$3.6M−75% | −$11.5M+126% | −$19.1M+259% | −$51.6M+959% |
| $0 | $1K | $0 | $0 | $0 | $1K+0% | $0 | $0 | |
| Net income | −$14.2M | −$5.1M | −$5.3M | −$4.9M | −$3.6M−75% | −$11.5M+126% | −$19.1M+259% | −$51.6M+959% |
| −$39.49 | n/a | −$14.79 | −$13.58 | −$0.61−99% | n/a | −$0.67−96% | −$1.71−87% | |
| 359.1K | n/a | 358.8K | 358.8K | 5.8M+1517% | n/a | 28.2M+7772% | 30.1M+8299% |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest LB Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LBRXLB Pharmaceuticals | $1.3B | n/m | n/a | n/m | n/m | n/m | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.7× | 1.9× | +6% | 2.0% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANIPANI Pharmaceuticals | $1.6B | 15.0× | 57.5× | 1.7× | +31% | 11.1% | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| HRMYHarmony Biosciences | $2.2B | 12.3× | 13.8× | 2.3× | +24% | 18.9% | |
| PBHPrestige Consumer Healthcare | $2.4B | 13.9× | 15.3× | 2.1× | −1% | 15.6% | |
| Peer median | $1.4B | 14.5× | 19.8× | 1.8× | +14% | 10.9% |
More on LB Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .